Restoration of natural IgM production from liver B cells by exogenous IL-18 improves the survival of burn-injured mice infected with Pseudomonas aeruginosa.
Pseudomonas aeruginosa is the most common bacterium of postburn infection. In the present study we investigated the immune mechanism of susceptibility to this type of postburn infection and also examined the efficacy of IL-18 treatment. C57BL/6 mice were challenged with P. aeruginosa on day 7 after burn injury. Although the burn-injured mice showed a poor survival rate after bacterial challenge, they retained their IFN-gamma production. The burned mice showed lower serum IgM levels and a poor IgM response following P. aeruginosa challenge in comparison with the sham mice, whereas IL-18 treatment after burn injury (alternate day injections for 1 wk) greatly improved the serum IgM levels, which are P. aeruginosa-independent natural IgM before bacterial challenge, thereby increasing the survival rate after the challenge. IL-18 treatment also induced specific IgM to P. aeruginosa in the sera 5 days after bacterial challenge in the burned mice. Interestingly, CD43(+)CD5(-)CD23(-)B220(dim) cells, namely B-1b cells, increased in the liver after the IL-18 treatment and were found to actively produce IgM in vitro without any additional stimulation. Furthermore, the IL-18 treatment up-regulated the neutrophil count and the C3a levels in the blood as a result of the increased IgM level, which may thus play a critical role in the opsonization and elimination of any invading bacteria. IL-18 treatment for the burned mice and their resultant natural IgM production were thus found to strengthen the host defense against P. aeruginosa infection.
Kinoshita
Manabu
M
Division of Basic Traumatology, Research Institute, National Defense Medical College, Namiki 3-2, Tokorozawa 359-8513, Japan.
Shinomiya
Nariyoshi
N
Ono
Satoshi
S
Tsujimoto
Hironori
H
Kawabata
Toshinobu
T
Matsumoto
Atsushi
A
Hiraide
Hoshio
H
Seki
Shuhji
S
D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology*; D002056:Burns / Q000150:complications / Q000276:immunology*; D015926:Complement C3a / Q000187:drug effects; D007075:Immunoglobulin M / Q000097:blood*; D020382:Interleukin-18 / Q000627:therapeutic use*; D008099:Liver / Q000166:cytology / Q000276:immunology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009504:Neutrophils / Q000187:drug effects; D011552:Pseudomonas Infections / Q000188:drug therapy*
D007075:Immunoglobulin M; D020382:Interleukin-18; D015926:Complement C3a